Formate Supplementation Enhances Antitumor CD8+ T-cell Fitness and Efficacy of PD-1 Blockade

被引:23
作者
Rowe, Jared H. [1 ,2 ,3 ]
Elia, Ilaria [4 ,5 ]
Shahid, Osmaan [2 ,3 ]
Gaudiano, Emily F. [2 ,3 ]
Sifnugel, Natalia E. [2 ,3 ]
Johnson, Sheila [4 ]
Reynolds, Amy G. [1 ]
Fung, Megan E. [2 ,3 ]
Joshi, Shakchhi [4 ]
LaFleur, Martin W. [2 ,3 ]
Park, Joon Seok [2 ,3 ]
Pauken, Kristen E. [2 ,3 ]
Rabinowitz, Joshua D. [6 ]
Freeman, Gordon J. [7 ]
Haigis, Marcia C. [4 ]
Sharpe, Arlene H. [2 ,3 ]
机构
[1] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA USA
[2] Blavatnik Inst, Harvard Med Sch, Dept Immunol, Boston, MA USA
[3] Lay Inst Immunol & Inflammat, Harvard Med Sch & Brigham & Womens Hosp, Boston, MA USA
[4] Blavatnik Inst, Harvard Med Sch, Dept Cell Biol, Boston, MA USA
[5] Dept Cellular & Mol Med, Leuven, Belgium
[6] Princeton Univ, Lewis Sigler Inst Integrat Genom, Princeton, NJ USA
[7] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
基金
美国国家卫生研究院;
关键词
ONE-CARBON METABOLISM; TUMOR MICROENVIRONMENT; SACCHAROMYCES-CEREVISIAE; NIVOLUMAB; SERINE; ACTIVATION; IPILIMUMAB;
D O I
10.1158/2159-8290.CD-22-1301
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Metabolic support, in the form of formate supplementation, combined with anti-PD-1 improves antitumor CD8+ T-cell fitness and tumor control, revealing a strategy that can be used to extend the benefits of anti-PD-1 therapy. Abstract The tumor microenvironment (TME) restricts antitumor CD8(+) T-cell function and immunotherapy responses. Cancer cells compromise the metabolic fitness of CD8(+) T cells within the TME, but the mechanisms are largely unknown. Here we demonstrate that one-carbon (1C) metabolism is enhanced in T cells in an antigen-specific manner. Therapeutic supplementation of 1C metabolism using formate enhances CD8(+) T-cell fitness and antitumor efficacy of PD-1 blockade in B16-OVA tumors. Formate supplementation drives transcriptional alterations in CD8(+) T-cell metabolism and increases gene signatures for cellular proliferation and activation. Combined formate and anti-PD-1 therapy increases tumor-infiltrating CD8(+) T cells, which are essential for enhanced tumor control. Our data demonstrate that formate provides metabolic support to CD8(+) T cells reinvigorated by anti-PD-1 to overcome a metabolic vulnerability in 1C metabolism in the TME to further improve T-cell function. Significance: This study identifies that deficiencies in 1C metabolism limit the efficacy of PD-1 blockade in B16-OVA tumors. Supplementing 1C metabolism with formate during anti-PD-1 therapy enhances CD8(+) T-cell fitness in the TME and CD8(+) T-cell-mediated tumor clearance. These findings demonstrate that formate supplementation can enhance exhausted CD8(+) T-cell function. See related commentary by Lin et al., p. 2507. This article is featured in Selected Articles from This Issue, p. 2489
引用
收藏
页码:2566 / 2583
页数:18
相关论文
共 50 条
[31]   PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer [J].
Kansy, Benjamin A. ;
Concha-Benavente, Fernando ;
Srivastava, Raghvendra M. ;
Jie, Hyun-Bae ;
Shayan, Gulidanna ;
Lei, Yu ;
Moskovitz, Jessica ;
Moy, Jennifer ;
Li, Jing ;
Brandau, Sven ;
Lang, Stephan ;
Schmitt, Nicole C. ;
Freeman, Gordon J. ;
Gooding, William E. ;
Clump, David A. ;
Ferris, Robert L. .
CANCER RESEARCH, 2017, 77 (22) :6353-6364
[32]   TIM-3 blockade enhances IL-12-dependent antitumor immunity by promoting CD8+ T cell and XCR1+ dendritic cell spatial co-localization [J].
Gardner, Alycia ;
Pulido, Alvaro de Mingo ;
Hanggi, Kay ;
Bazargan, Sarah ;
Onimus, Alexis ;
Kasprzak, Agnieszka ;
Conejo-Garcia, Jose R. ;
Rejniak, Katarzyna A. ;
Ruffell, Brian .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (01)
[33]   CD8+ T-cell senescence: no role for mTOR [J].
Henson, Sian M. .
BIOCHEMICAL SOCIETY TRANSACTIONS, 2015, 43 :734-739
[34]   PD-1/PD-L1 Pathway Modulates Macrophage Susceptibility to Mycobacterium tuberculosis Specific CD8+ T cell Induced Death [J].
Veronica Suarez, Guadalupe ;
Melucci Ganzarain, Claudia del Carmen ;
Belen Vecchione, Maria ;
Ariel Trifone, Cesar ;
Franco, Jose Luis Marin ;
Genoula, Melanie ;
Jose Morana, Eduardo ;
Balboa, Luciana ;
Florencia Quiroga, Maria .
SCIENTIFIC REPORTS, 2019, 9 (1)
[35]   β-Adrenergic Signaling Impairs Antitumor CD8+ T-cell Responses to B-cell Lymphoma Immunotherapy [J].
Nissen, Michael D. ;
Sloan, Erica K. ;
Mattarollo, Stephen R. .
CANCER IMMUNOLOGY RESEARCH, 2018, 6 (01) :98-109
[36]   A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1 [J].
Ngiow, Shin Foong ;
Young, Arabella ;
Jacquelot, Nicolas ;
Yamazaki, Takahiro ;
Enot, David ;
Zitvogel, Laurence ;
Smyth, Mark J. .
CANCER RESEARCH, 2015, 75 (18) :3800-3811
[37]   Type 1 interferon-induced IL-7 maintains CD8+ T-cell responses and homeostasis by suppressing PD-1 expression in viral hepatitis [J].
Hou, Lifei ;
Jie, Zuliang ;
Liang, Yuejin ;
Desai, Mayura ;
Soong, Lynn ;
Sun, Jiaren .
CELLULAR & MOLECULAR IMMUNOLOGY, 2015, 12 (02) :213-221
[38]   IFN-γ down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer [J].
Guoping Ding ;
Tao Shen ;
Chen Yan ;
Mingjie Zhang ;
Zhengrong Wu ;
Liping Cao .
BMC Cancer, 19
[39]   Anti-4-1BBxPDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD1 Blockade [J].
Jeon, Seung Hyuck ;
You, Gihoon ;
Park, Junsik ;
Chung, Youseung ;
Park, Kyungjin ;
Kim, Hyunjoo ;
Jeon, Jaehyoung ;
Kim, Youngkwang ;
Son, Woo-Chan ;
Jeong, Da Som ;
Shin, Eui-Cheol ;
Lee, Jung-Yun ;
Han, Dai Hoon ;
Jung, Jaeho ;
Park, Su-Hyung .
CLINICAL CANCER RESEARCH, 2024, 30 (18) :4155-4166
[40]   CD147 regulates antitumor CD8+ T-cell responses to facilitate tumor-immune escape [J].
Chen, Yatong ;
Xu, Jing ;
Wu, Xiaodong ;
Yao, Hui ;
Yan, Zhou ;
Guo, Ting ;
Wang, Wenjing ;
Wang, Peixiao ;
Li, Yu ;
Yang, Xiangmin ;
Li, Hao ;
Bian, Huijie ;
Chen, Zhi-Nan .
CELLULAR & MOLECULAR IMMUNOLOGY, 2021, 18 (08) :1995-2009